Galectin-1 improves cognition and reduces amyloid-β deposits in an animal model of Alzheimer's disease possibly by modulating microglia phenotype and increasing Aβ clearance
- Autores
- Presa, Jessica Lorena; Pomilio, Carlos Javier; Vinuesa, María Angeles; Bentivegna, Melisa Inés María; Alaimo, Agustina; Gregosa Merlino, Amal Patricio; Beauquis, Juan; Kwang, Sik Kim; Rabinovich, Gabriel Adrián; Saravia, Flavia Eugenia
- Año de publicación
- 2019
- Idioma
- inglés
- Tipo de recurso
- documento de conferencia
- Estado
- versión publicada
- Descripción
- Alzheimer's disease (AD) is the most common form of dementia associated with an imbalanced production and clearance of amyloid-β peptides (Aβ). Amyloid deposition and neuroinflammation are recognized hallmarks in AD, affecting mainly brain cortex and hippocampus, in addition to microvascular alterations and dysfunction of the blood-brain barrier (BBB). The glycan-binding protein galectin-1 (Gal1) modulates immune and endothelial cells in nervous system compartments, where a neuroprotective role was proposed in autoimmune encephalomyelitis. We study the impact of Gal1 on the cognitive and histopathological state of AD mice. We administered Gal1 (9 i.p. injections of 100 ug/dose) or vehicle during 3 weeks to 12 months-old PDAPPJ20 transgenic mice, or non-transgenic controls. The Gal1 treated group significantly improved cognitive response in the Novel Object Location Recognition test (p < 0.05). Amyloid+ area in the hippocampus was decreased by 53,5%. Microglia is actively involved in Aβ phagocytosis. Gal1 treatment induced a reduction in the microglial activation score employing morphological analysis in the dentate gyrus. The integrity of the BBB is essential to Aβ clearance via the glymphatic system but could be altered by perivascular Aβ deposits-mostly Aβ1–40. Using tomato lectin to label the hippocampal vasculature coupled with immunofluorescence against Aβ peptides, we found a 30% decrease of perivascular Aβ (p < 0.05) in Gal1 treated mice, without affecting vascular density, which could indicate augmented clearance. We are currently working to determine mice BBB integrity employing Evans Blue intravenous injections and exploring its permeability to cerebral parenchyma, and using an in vitro BBB model to determine whether Aβ1–40 alters it at non toxic concentrations. Human brain microvascular endothelial cells on a transwell membrane are used, monitored by Transendothelial Electrical Resistance (TEER) and permeability essays. We are also investigating possible protective effects of Gal1 on barrier's integrity.
Fil: Presa, Jessica Lorena. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Pomilio, Carlos Javier. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Vinuesa, María Angeles. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Bentivegna, Melisa Inés María. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Alaimo, Agustina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Ciudad Universitaria. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales; Argentina
Fil: Gregosa Merlino, Amal Patricio. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Beauquis, Juan. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Kwang, Sik Kim. University Johns Hopkins; Estados Unidos
Fil: Rabinovich, Gabriel Adrián. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Saravia, Flavia Eugenia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
The 10th International Brain Research Organization (IBRO) World Congress of Neuroscience
Daegu
Corea del Sur
International Brain Research Organization
Korea Brain Research Institute
The Korean Society for Brain and Neural Sciences - Materia
-
Alzheimer
Blood-brain-barrier
Microglia
Galectin-1 - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
.jpg)
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/130220
Ver los metadatos del registro completo
| id |
CONICETDig_b432060f02f655c7a7bfd170934d490a |
|---|---|
| oai_identifier_str |
oai:ri.conicet.gov.ar:11336/130220 |
| network_acronym_str |
CONICETDig |
| repository_id_str |
3498 |
| network_name_str |
CONICET Digital (CONICET) |
| spelling |
Galectin-1 improves cognition and reduces amyloid-β deposits in an animal model of Alzheimer's disease possibly by modulating microglia phenotype and increasing Aβ clearancePresa, Jessica LorenaPomilio, Carlos JavierVinuesa, María AngelesBentivegna, Melisa Inés MaríaAlaimo, AgustinaGregosa Merlino, Amal PatricioBeauquis, JuanKwang, Sik KimRabinovich, Gabriel AdriánSaravia, Flavia EugeniaAlzheimerBlood-brain-barrierMicrogliaGalectin-1https://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Alzheimer's disease (AD) is the most common form of dementia associated with an imbalanced production and clearance of amyloid-β peptides (Aβ). Amyloid deposition and neuroinflammation are recognized hallmarks in AD, affecting mainly brain cortex and hippocampus, in addition to microvascular alterations and dysfunction of the blood-brain barrier (BBB). The glycan-binding protein galectin-1 (Gal1) modulates immune and endothelial cells in nervous system compartments, where a neuroprotective role was proposed in autoimmune encephalomyelitis. We study the impact of Gal1 on the cognitive and histopathological state of AD mice. We administered Gal1 (9 i.p. injections of 100 ug/dose) or vehicle during 3 weeks to 12 months-old PDAPPJ20 transgenic mice, or non-transgenic controls. The Gal1 treated group significantly improved cognitive response in the Novel Object Location Recognition test (p < 0.05). Amyloid+ area in the hippocampus was decreased by 53,5%. Microglia is actively involved in Aβ phagocytosis. Gal1 treatment induced a reduction in the microglial activation score employing morphological analysis in the dentate gyrus. The integrity of the BBB is essential to Aβ clearance via the glymphatic system but could be altered by perivascular Aβ deposits-mostly Aβ1–40. Using tomato lectin to label the hippocampal vasculature coupled with immunofluorescence against Aβ peptides, we found a 30% decrease of perivascular Aβ (p < 0.05) in Gal1 treated mice, without affecting vascular density, which could indicate augmented clearance. We are currently working to determine mice BBB integrity employing Evans Blue intravenous injections and exploring its permeability to cerebral parenchyma, and using an in vitro BBB model to determine whether Aβ1–40 alters it at non toxic concentrations. Human brain microvascular endothelial cells on a transwell membrane are used, monitored by Transendothelial Electrical Resistance (TEER) and permeability essays. We are also investigating possible protective effects of Gal1 on barrier's integrity.Fil: Presa, Jessica Lorena. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Pomilio, Carlos Javier. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Vinuesa, María Angeles. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Bentivegna, Melisa Inés María. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Alaimo, Agustina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Ciudad Universitaria. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales; ArgentinaFil: Gregosa Merlino, Amal Patricio. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Beauquis, Juan. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Kwang, Sik Kim. University Johns Hopkins; Estados UnidosFil: Rabinovich, Gabriel Adrián. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Saravia, Flavia Eugenia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaThe 10th International Brain Research Organization (IBRO) World Congress of NeuroscienceDaeguCorea del SurInternational Brain Research OrganizationKorea Brain Research InstituteThe Korean Society for Brain and Neural SciencesElsevier2019info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/conferenceObjectCongresoJournalhttp://purl.org/coar/resource_type/c_5794info:ar-repo/semantics/documentoDeConferenciaapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/130220Galectin-1 improves cognition and reduces amyloid-β deposits in an animal model of Alzheimer's disease possibly by modulating microglia phenotype and increasing Aβ clearance; The 10th International Brain Research Organization (IBRO) World Congress of Neuroscience; Daegu; Corea del Sur; 2019; S477-S4772451-8301CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S2451830119315547info:eu-repo/semantics/altIdentifier/doi/10.1016/j.ibror.2019.07.1502Internacionalinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-22T12:08:26Zoai:ri.conicet.gov.ar:11336/130220instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-22 12:08:26.626CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
| dc.title.none.fl_str_mv |
Galectin-1 improves cognition and reduces amyloid-β deposits in an animal model of Alzheimer's disease possibly by modulating microglia phenotype and increasing Aβ clearance |
| title |
Galectin-1 improves cognition and reduces amyloid-β deposits in an animal model of Alzheimer's disease possibly by modulating microglia phenotype and increasing Aβ clearance |
| spellingShingle |
Galectin-1 improves cognition and reduces amyloid-β deposits in an animal model of Alzheimer's disease possibly by modulating microglia phenotype and increasing Aβ clearance Presa, Jessica Lorena Alzheimer Blood-brain-barrier Microglia Galectin-1 |
| title_short |
Galectin-1 improves cognition and reduces amyloid-β deposits in an animal model of Alzheimer's disease possibly by modulating microglia phenotype and increasing Aβ clearance |
| title_full |
Galectin-1 improves cognition and reduces amyloid-β deposits in an animal model of Alzheimer's disease possibly by modulating microglia phenotype and increasing Aβ clearance |
| title_fullStr |
Galectin-1 improves cognition and reduces amyloid-β deposits in an animal model of Alzheimer's disease possibly by modulating microglia phenotype and increasing Aβ clearance |
| title_full_unstemmed |
Galectin-1 improves cognition and reduces amyloid-β deposits in an animal model of Alzheimer's disease possibly by modulating microglia phenotype and increasing Aβ clearance |
| title_sort |
Galectin-1 improves cognition and reduces amyloid-β deposits in an animal model of Alzheimer's disease possibly by modulating microglia phenotype and increasing Aβ clearance |
| dc.creator.none.fl_str_mv |
Presa, Jessica Lorena Pomilio, Carlos Javier Vinuesa, María Angeles Bentivegna, Melisa Inés María Alaimo, Agustina Gregosa Merlino, Amal Patricio Beauquis, Juan Kwang, Sik Kim Rabinovich, Gabriel Adrián Saravia, Flavia Eugenia |
| author |
Presa, Jessica Lorena |
| author_facet |
Presa, Jessica Lorena Pomilio, Carlos Javier Vinuesa, María Angeles Bentivegna, Melisa Inés María Alaimo, Agustina Gregosa Merlino, Amal Patricio Beauquis, Juan Kwang, Sik Kim Rabinovich, Gabriel Adrián Saravia, Flavia Eugenia |
| author_role |
author |
| author2 |
Pomilio, Carlos Javier Vinuesa, María Angeles Bentivegna, Melisa Inés María Alaimo, Agustina Gregosa Merlino, Amal Patricio Beauquis, Juan Kwang, Sik Kim Rabinovich, Gabriel Adrián Saravia, Flavia Eugenia |
| author2_role |
author author author author author author author author author |
| dc.subject.none.fl_str_mv |
Alzheimer Blood-brain-barrier Microglia Galectin-1 |
| topic |
Alzheimer Blood-brain-barrier Microglia Galectin-1 |
| purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.1 https://purl.org/becyt/ford/3 |
| dc.description.none.fl_txt_mv |
Alzheimer's disease (AD) is the most common form of dementia associated with an imbalanced production and clearance of amyloid-β peptides (Aβ). Amyloid deposition and neuroinflammation are recognized hallmarks in AD, affecting mainly brain cortex and hippocampus, in addition to microvascular alterations and dysfunction of the blood-brain barrier (BBB). The glycan-binding protein galectin-1 (Gal1) modulates immune and endothelial cells in nervous system compartments, where a neuroprotective role was proposed in autoimmune encephalomyelitis. We study the impact of Gal1 on the cognitive and histopathological state of AD mice. We administered Gal1 (9 i.p. injections of 100 ug/dose) or vehicle during 3 weeks to 12 months-old PDAPPJ20 transgenic mice, or non-transgenic controls. The Gal1 treated group significantly improved cognitive response in the Novel Object Location Recognition test (p < 0.05). Amyloid+ area in the hippocampus was decreased by 53,5%. Microglia is actively involved in Aβ phagocytosis. Gal1 treatment induced a reduction in the microglial activation score employing morphological analysis in the dentate gyrus. The integrity of the BBB is essential to Aβ clearance via the glymphatic system but could be altered by perivascular Aβ deposits-mostly Aβ1–40. Using tomato lectin to label the hippocampal vasculature coupled with immunofluorescence against Aβ peptides, we found a 30% decrease of perivascular Aβ (p < 0.05) in Gal1 treated mice, without affecting vascular density, which could indicate augmented clearance. We are currently working to determine mice BBB integrity employing Evans Blue intravenous injections and exploring its permeability to cerebral parenchyma, and using an in vitro BBB model to determine whether Aβ1–40 alters it at non toxic concentrations. Human brain microvascular endothelial cells on a transwell membrane are used, monitored by Transendothelial Electrical Resistance (TEER) and permeability essays. We are also investigating possible protective effects of Gal1 on barrier's integrity. Fil: Presa, Jessica Lorena. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina Fil: Pomilio, Carlos Javier. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina Fil: Vinuesa, María Angeles. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina Fil: Bentivegna, Melisa Inés María. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina Fil: Alaimo, Agustina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Ciudad Universitaria. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales; Argentina Fil: Gregosa Merlino, Amal Patricio. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina Fil: Beauquis, Juan. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina Fil: Kwang, Sik Kim. University Johns Hopkins; Estados Unidos Fil: Rabinovich, Gabriel Adrián. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina Fil: Saravia, Flavia Eugenia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina The 10th International Brain Research Organization (IBRO) World Congress of Neuroscience Daegu Corea del Sur International Brain Research Organization Korea Brain Research Institute The Korean Society for Brain and Neural Sciences |
| description |
Alzheimer's disease (AD) is the most common form of dementia associated with an imbalanced production and clearance of amyloid-β peptides (Aβ). Amyloid deposition and neuroinflammation are recognized hallmarks in AD, affecting mainly brain cortex and hippocampus, in addition to microvascular alterations and dysfunction of the blood-brain barrier (BBB). The glycan-binding protein galectin-1 (Gal1) modulates immune and endothelial cells in nervous system compartments, where a neuroprotective role was proposed in autoimmune encephalomyelitis. We study the impact of Gal1 on the cognitive and histopathological state of AD mice. We administered Gal1 (9 i.p. injections of 100 ug/dose) or vehicle during 3 weeks to 12 months-old PDAPPJ20 transgenic mice, or non-transgenic controls. The Gal1 treated group significantly improved cognitive response in the Novel Object Location Recognition test (p < 0.05). Amyloid+ area in the hippocampus was decreased by 53,5%. Microglia is actively involved in Aβ phagocytosis. Gal1 treatment induced a reduction in the microglial activation score employing morphological analysis in the dentate gyrus. The integrity of the BBB is essential to Aβ clearance via the glymphatic system but could be altered by perivascular Aβ deposits-mostly Aβ1–40. Using tomato lectin to label the hippocampal vasculature coupled with immunofluorescence against Aβ peptides, we found a 30% decrease of perivascular Aβ (p < 0.05) in Gal1 treated mice, without affecting vascular density, which could indicate augmented clearance. We are currently working to determine mice BBB integrity employing Evans Blue intravenous injections and exploring its permeability to cerebral parenchyma, and using an in vitro BBB model to determine whether Aβ1–40 alters it at non toxic concentrations. Human brain microvascular endothelial cells on a transwell membrane are used, monitored by Transendothelial Electrical Resistance (TEER) and permeability essays. We are also investigating possible protective effects of Gal1 on barrier's integrity. |
| publishDate |
2019 |
| dc.date.none.fl_str_mv |
2019 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/publishedVersion info:eu-repo/semantics/conferenceObject Congreso Journal http://purl.org/coar/resource_type/c_5794 info:ar-repo/semantics/documentoDeConferencia |
| status_str |
publishedVersion |
| format |
conferenceObject |
| dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/130220 Galectin-1 improves cognition and reduces amyloid-β deposits in an animal model of Alzheimer's disease possibly by modulating microglia phenotype and increasing Aβ clearance; The 10th International Brain Research Organization (IBRO) World Congress of Neuroscience; Daegu; Corea del Sur; 2019; S477-S477 2451-8301 CONICET Digital CONICET |
| url |
http://hdl.handle.net/11336/130220 |
| identifier_str_mv |
Galectin-1 improves cognition and reduces amyloid-β deposits in an animal model of Alzheimer's disease possibly by modulating microglia phenotype and increasing Aβ clearance; The 10th International Brain Research Organization (IBRO) World Congress of Neuroscience; Daegu; Corea del Sur; 2019; S477-S477 2451-8301 CONICET Digital CONICET |
| dc.language.none.fl_str_mv |
eng |
| language |
eng |
| dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S2451830119315547 info:eu-repo/semantics/altIdentifier/doi/10.1016/j.ibror.2019.07.1502 |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
| eu_rights_str_mv |
openAccess |
| rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
| dc.format.none.fl_str_mv |
application/pdf application/pdf application/pdf application/pdf application/pdf |
| dc.coverage.none.fl_str_mv |
Internacional |
| dc.publisher.none.fl_str_mv |
Elsevier |
| publisher.none.fl_str_mv |
Elsevier |
| dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
| reponame_str |
CONICET Digital (CONICET) |
| collection |
CONICET Digital (CONICET) |
| instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
| repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
| repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
| _version_ |
1846782455528292352 |
| score |
12.982451 |